COST-UTILITY ANALYSIS OF LORLATINIB FOR FIRST-LINE TREATMENT FOR ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA

被引：0
|
作者：
He, X. [1 ]
Fu, S. [1 ]
机构：
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE69
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] LORLATINIB AS A FIRST-LINE TREATMENT FOR ALK plus ADVANCED NON-SMALL CELL LUNG CANCER: A COSTEFFECTIVENESS ANALYSIS IN SPAIN
    Presa, M.
    Vicente, D.
    Calles, A.
    Salinas-Ortega, L.
    Naik, J.
    Garcia, L. F.
    Soto, J.
    VALUE IN HEALTH, 2022, 25 (12) : S90 - S91
  • [2] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
    Lin, Jessica J.
    Gainor, Justin F.
    LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
  • [3] New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer
    Pasquier, Corentin
    Basse, Clemence
    BULLETIN DU CANCER, 2022, 109 (09) : 877 - 878
  • [4] ALECTINIB, BRIGATINIB, AND LORLATINIB AS FIRST-LINE THERAPIES FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS
    Mudumba, R.
    Nieva, J. J.
    Padula, W.
    VALUE IN HEALTH, 2024, 27 (12) : S81 - S81
  • [5] COST-EFFECTIVENESS OF LORLATINIB IN SECOND-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
    Shi, S.
    Jiang, Y.
    VALUE IN HEALTH, 2023, 26 (12) : S201 - S201
  • [6] Lorlatinib in the first-line treatment of ALK-positive metastatic/advanced non-small-cell lung cancer: A budget impact analysis
    Abrahami, Devin
    Thakkar, Sheena
    Bartolome, Lauren
    Kelton, John Mark
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 388 - 388
  • [7] Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
    Yang, X.
    Dong, X.
    Liu, Y.
    Jin, B.
    Wang, J.
    Wang, Y.
    Zhang, Y.
    Zhuo, M.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S663 - S663
  • [8] Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
    Chen, Ting
    Xie, Ruixiang
    Zhao, Qiuling
    Cai, Hongfu
    Yang, Lin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
    Permsuwan, Unchalee
    Thongprasert, Sumitra
    Sirichanchuen, Buntitabhon
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 9 - 16
  • [10] COST-UTILITY ANALYSIS OF GEFITINIB AND EGFR MUTATION TESTING AS THE FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    VALUE IN HEALTH, 2017, 20 (05) : A112 - A112
12345